tiprankstipranks
Trending News
More News >
Arrowhead Pharmaceuticals, Inc. (GB:0HI3)
:0HI3
UK Market

Arrowhead Pharmaceuticals (0HI3) Share Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

0HI3 Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
8 Buy
4 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Arrowhead
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HI3 Stock 12 Month Forecast

Average Price Target

$39.90
▲( 164.59% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $39.90 with a high forecast of $80.00 and a low forecast of $17.00. The average price target represents a 164.59% change from the last price of $15.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","30":"$30","47":"$47","64":"$64","81":"$81"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,30,47,64,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.114,19.182153846153845,24.250307692307693,29.31846153846154,34.38661538461538,39.45476923076923,44.52292307692308,49.591076923076926,54.659230769230774,59.72738461538462,64.79553846153847,69.8636923076923,74.93184615384615,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.114,16.097538461538463,18.081076923076925,20.064615384615387,22.048153846153845,24.03169230769231,26.01523076923077,27.99876923076923,29.982307692307693,31.965846153846154,33.949384615384616,35.932923076923075,37.91646153846153,{"y":39.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.114,14.336,14.558,14.780000000000001,15.002,15.224,15.446,15.668000000000001,15.89,16.112000000000002,16.334,16.556,16.778,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.107,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.778,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.249,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.631,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.054,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.351,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.455,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.855,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.114,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$39.90Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0HI3
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$80
Buy
430.50%
Upside
Reiterated
05/20/25
UBS
$71$63
Buy
317.77%
Upside
Reiterated
05/14/25
B.Riley Financial Analyst forecast on GB:0HI3
Mayank MamtaniB.Riley Financial
B.Riley Financial
$38
Buy
151.99%
Upside
Initiated
05/14/25
Cantor Fitzgerald Analyst forecast on GB:0HI3
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
TD Cowen
Buy
Reiterated
05/13/25
Morgan Stanley Analyst forecast on GB:0HI3
Michael UlzMorgan Stanley
Morgan Stanley
$29
Hold
92.31%
Upside
Reiterated
05/13/25
RBC Capital Analyst forecast on GB:0HI3
Luca IssiRBC Capital
RBC Capital
$40
Buy
165.25%
Upside
Reiterated
05/13/25
Bank of America Securities Analyst forecast on GB:0HI3
Jason GerberryBank of America Securities
Bank of America Securities
$41$39
Buy
158.62%
Upside
Reiterated
05/12/25
Citi
$17
Hold
12.73%
Upside
Reiterated
05/12/25
Leerink Partners Analyst forecast on GB:0HI3
Mani ForooharLeerink Partners
Leerink Partners
$22
Hold
45.89%
Upside
Reiterated
05/12/25
Goldman Sachs Analyst forecast on GB:0HI3
Andrea TanGoldman Sachs
Goldman Sachs
$26
Hold
72.41%
Upside
Reiterated
03/10/25
Piper Sandler Analyst forecast on GB:0HI3
Edward TenthoffPiper Sandler
Piper Sandler
$45
Buy
198.41%
Upside
Reiterated
02/26/25
Chardan Capital Analyst forecast on GB:0HI3
Keay NakaeChardan Capital
Chardan Capital
$60
Buy
297.88%
Upside
Reiterated
02/11/25
Bernstein
$24
Hold
59.15%
Upside
Reiterated
11/27/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on GB:0HI3
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$80
Buy
430.50%
Upside
Reiterated
05/20/25
UBS
$71$63
Buy
317.77%
Upside
Reiterated
05/14/25
B.Riley Financial Analyst forecast on GB:0HI3
Mayank MamtaniB.Riley Financial
B.Riley Financial
$38
Buy
151.99%
Upside
Initiated
05/14/25
Cantor Fitzgerald Analyst forecast on GB:0HI3
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
05/13/25
TD Cowen
Buy
Reiterated
05/13/25
Morgan Stanley Analyst forecast on GB:0HI3
Michael UlzMorgan Stanley
Morgan Stanley
$29
Hold
92.31%
Upside
Reiterated
05/13/25
RBC Capital Analyst forecast on GB:0HI3
Luca IssiRBC Capital
RBC Capital
$40
Buy
165.25%
Upside
Reiterated
05/13/25
Bank of America Securities Analyst forecast on GB:0HI3
Jason GerberryBank of America Securities
Bank of America Securities
$41$39
Buy
158.62%
Upside
Reiterated
05/12/25
Citi
$17
Hold
12.73%
Upside
Reiterated
05/12/25
Leerink Partners Analyst forecast on GB:0HI3
Mani ForooharLeerink Partners
Leerink Partners
$22
Hold
45.89%
Upside
Reiterated
05/12/25
Goldman Sachs Analyst forecast on GB:0HI3
Andrea TanGoldman Sachs
Goldman Sachs
$26
Hold
72.41%
Upside
Reiterated
03/10/25
Piper Sandler Analyst forecast on GB:0HI3
Edward TenthoffPiper Sandler
Piper Sandler
$45
Buy
198.41%
Upside
Reiterated
02/26/25
Chardan Capital Analyst forecast on GB:0HI3
Keay NakaeChardan Capital
Chardan Capital
$60
Buy
297.88%
Upside
Reiterated
02/11/25
Bernstein
$24
Hold
59.15%
Upside
Reiterated
11/27/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arrowhead Pharmaceuticals

1 Month
xxx
Success Rate
13/24 ratings generated profit
54%
Average Return
-1.68%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of -1.68% per trade.
3 Months
xxx
Success Rate
21/40 ratings generated profit
53%
Average Return
+7.21%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.50% of your transactions generating a profit, with an average return of +7.21% per trade.
1 Year
Keay NakaeChardan Capital
Success Rate
19/40 ratings generated profit
48%
Average Return
+27.62%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +27.62% per trade.
2 Years
xxx
Success Rate
13/40 ratings generated profit
33%
Average Return
+44.65%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 32.50% of your transactions generating a profit, with an average return of +44.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HI3 Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
12
15
17
13
13
Buy
3
2
1
1
3
Hold
9
7
4
5
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
24
22
19
24
In the current month, 0HI3 has received 16 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 0HI3 average Analyst price target in the past 3 months is 39.90.
Each month's total comprises the sum of three months' worth of ratings.

0HI3 Financial Forecast

0HI3 Earnings Forecast

Next quarter’s earnings estimate for 0HI3 is -$0.95 with a range of -$1.29 to $0.36. The previous quarter’s EPS was $2.75. 0HI3 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year 0HI3 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0HI3 is -$0.95 with a range of -$1.29 to $0.36. The previous quarter’s EPS was $2.75. 0HI3 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year 0HI3 has Outperformed its overall industry.

0HI3 Sales Forecast

Next quarter’s sales forecast for 0HI3 is $46.83M with a range of $0.00 to $217.05M. The previous quarter’s sales results were $542.71M. 0HI3 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year 0HI3 has Outperformed its overall industry.
Next quarter’s sales forecast for 0HI3 is $46.83M with a range of $0.00 to $217.05M. The previous quarter’s sales results were $542.71M. 0HI3 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year 0HI3 has Outperformed its overall industry.

0HI3 Stock Forecast FAQ

What is GB:0HI3’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals, Inc.’s 12-month average price target is 39.90.
    What is GB:0HI3’s upside potential, based on the analysts’ average price target?
    Arrowhead Pharmaceuticals, Inc. has 164.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Arrowhead Pharmaceuticals, Inc. a Buy, Sell or Hold?
          Arrowhead Pharmaceuticals, Inc. has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Arrowhead Pharmaceuticals, Inc.’s share price target?
            The average share price target for Arrowhead Pharmaceuticals, Inc. is 39.90. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $80.00 ,and the lowest forecast is $17.00. The average share price target represents 164.59% Increase from the current price of $15.08.
              What do analysts say about Arrowhead Pharmaceuticals, Inc.?
              Arrowhead Pharmaceuticals, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Arrowhead Pharmaceuticals, Inc.?
                To buy shares of GB:0HI3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis